Zydus and Zhuhai Beihai Biotech Forge US Cancer Drug Partnership

Zydus Lifesciences' subsidiary entered into an agreement with Zhuhai Beihai Biotech to market Beizray, a cancer drug, in the US. Zhuhai will manufacture and supply, while Zydus handles US commercialization. Beizray targets multiple cancer types, providing patients with an important alternative treatment.

Zydus Lifesciences has announced a significant partnership with Zhuhai Beihai Biotech Co to market an innovative cancer drug in the United States. This collaboration sees Zydus Lifesciences Global FZE obtaining exclusive licensing rights for Beizray (Albumin Solubilized Docetaxel injection), which promises substantial clinical advantages.

Under the strategic agreement, manufacturing and supply responsibilities will rest with Zhuhai Beihai Biotech, while Zydus will spearhead the commercialization efforts. The financial terms include upfront payments, milestone-based sales targets, and a profit-sharing model, highlighting the mutual benefits of this international arrangement.

Beizray is indicated for a range of cancers, such as breast, non-small cell lung, prostate, gastric adenocarcinoma, and head and neck cancers. This deal is poised to expand patient access to innovative therapies, aligning with Zydus' mission to address high unmet medical needs in the US healthcare market.